Overview

SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome

Status:
Terminated
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate the efficacy of the treatment in response rate terms. Otherwise this study wants to evaluate the safety of the treatment.
Phase:
Phase 2
Details
Lead Sponsor:
PETHEMA Foundation
Collaborators:
Celgene Corporation
Roche Pharma AG
Treatments:
Azacitidine
Epoetin Alfa